Reported Saturday, Boston Scientific's HI-PEITHO Trial Shows EKOS Endovascular System Superior To Standard Of Care, Delivering 61% Reduction In Primary Endpoint Events In Acute Pulmonary Embolism

Boston Scientific's HI-PEITHO trial demonstrated that the EKOS Endovascular System, when used in conjunction with anticoagulation, resulted in a 61% reduction in primary endpoint events for patients with acute pulmonary embolism compared to standard anticoagulation treatment alone. These findings were presented at the ACC.26 conference and published in The New England Journal of Medicine.